Interferon -gamma ( IFNg ) and tumor necrosis factor -alpha ( TNFa ) are potent immunostimulatory cytokines with demonstrated tumoricidal effects in a variety of cancers. With the aim of investigating their ability to generate antitumor immune responses in malignant brain tumors, we describe the use of in situ adenoviral -mediated IFNg and TNFa gene transfer in glioma -bearing rodents. Survival was prolonged in mice treated with AdmIFNg or AdTNFa compared to AdLacZ -and saline -inoculated controls, and AdmIFNg -or AdTNFa -treated animals revealed significantly smaller tumors. These effects were accompanied by significant upregulation of tumor MHC -I expression in AdmIFNg -inoculated animals, and of MHC -II in AdTNFa -treated tumors. Significantly enhanced intratumoral infiltration with CD4 + and CD8 + T cells was visible in animals treated with AdmIFNg, AdTNFa, or a combination of AdmIFNg and AdTNFa. In addition, AdTNFa therapy down -regulated the expression of endothelial Fas ligand, a cell membrane protein implicated as a contributor to immune privilege in cancer. These findings demonstrate the effectiveness of local IFNg and TNFa gene transfer as a treatment strategy for glioma and illustrate possible physiological pathways responsible for the therapeutic benefit observed.
T he use of cytokine therapy for cancer has received considerable attention, with the use of a variety of agents in a wide range of neoplastic models. The use of direct recombinant cytokine therapy, although highly effective at eradicating tumors in rodents, 1,2 is generally of limited applicability in human cancers either due to issues of toxicity or subtherapeutic protein half -life. 3, 4 With particular regard to malignant glioma, the use of immunomodulatory cytokines must also take into account the partial immune privileged status of the central nervous system and the documented ability of brain tumors to actively suppress host immune function. 5 -7 There has, therefore, been increased interest in developing locoregional cytokine delivery paradigms for brain tumors, which are able to circumvent and /or undermine the physiochemical barriers to immune access associated with gliomas.
Cytokines mediate their tumoricidal activity chiefly through the stimulation of antitumor immunity. Interleukin-2, 8, 9 interleukin -4, 10,11 and interleukin -12, 12,13 among others, have all shown significant potency by stimulating immune responses against gliomas. Certain cytokines such as interferon -gamma (IFNg ) and tumor necrosis factor-alpha ( TNFa) have additionally demonstrated the ability to exhibit direct nonimmune-mediated toxicity to tumors in vivo either by inhibiting neovascular angiogenesis, 14, 15 or by inducing tumor cell 16 or endothelial cell 17 death. IFNg is a key cytokine involved in Th -1 cell -mediated antitumor activity 18 and has also been implicated as an antiangiogenic factor. 19 TNFa is a powerful immunomodulatory agent, which facilitates immune cell extravasation by up-regulating adhesion molecule expression 20 and is involved in the regulation of multiple immune pathways including cell growth, inflammation, and autoimmunity. 21 TNFa has also been shown to cause direct necrosis in neoplastic cells. 22 Both IFNg and TNFa modulate cell surface expression of MHC -I and -II, which are key molecules involved in the recognition of antigen by and activation of tumor-specific T cells. 20, 23 In intracranial tumor models, IFNg and TNFa have shown therapeutic benefit by promoting both immune 24 and nonimmune 25, 26 antitumor activity. With the aim of further investigating the tumoricidal mechanisms and therapeutic uses of IFNg and TNFa, separately and in combination, for glioma, we describe the use of replicationdeficient adenoviral vectors encoding either IFNg ( AdmIFNg ) or TNFa (AdTNFa) for the treatment of a syngeneic murine glioma model. We demonstrate that intratumoral delivery of AdmIFNg and /or AdTNFa reduced tumor volume and prolonged survival. These effects were accompanied by up -regulation of MHC -I and -II molecules on glioma cells and significant infiltration of tumors by CD4 + and CD8 + T cells. We also demonstrate that AdTNFa is able to down -regulate the expression on tumor-associated endothelium of Fas ligand ( FasL ), a proapoptotic cell surface protein capable of inducing death in T cells attempting to translocate across vessel walls. 27 
Materials and methods

Virus and cell culture
The recombinant replication -deficient adenoviral vectors bearing the gene for murine IFNg ( AdmIFNg ) and the gene for human TNFa (AdTNFa) were the kind gifts of Dr Luis P Villareal ( Irvine, CA ). A replication -deficient adenovirus with the LacZ gene ( AdLacZ ) was constructed as described previously.
28 GL26 cells ( murine glioma ) and RG -2 cells ( rat glioma ) were grown in DMEM (Gibco BRL, Gaithersburg, MD ) supplemented with 10% fetal bovine serum ( Gemini Bioproducts, Calabasas, CA ). Cell culture medium were supplemented with 2 mM L -glutamine, 100 g/mL penicillin, and 100 U / mL streptomycin (Gibco BRL ). TNFa by AdmIFNg -and  AdTNFa -infected glioma cells   10 5 GL26 glioma cells were infected with AdmIFNg and /or AdTNFa at different multiplicities of infection ( MOIs ) in a total volume of 0.1 mL. After 1 hour, the viral supernatant was replaced with cell culture medium. Forty -eight hours later, the supernatant was again replaced with fresh media and, 24 hours subsequently, the medium was collected and tested for IFNg and TNFa content using an enzyme -linked immunosorbent assay (ELISA) (BD Pharmingen, San Diego, CA).
Secretion of IFNg and
In situ adenoviral IFNg and TNFa gene transfer to intracranial glioma using AdmIFNg and AdTNFa Six -to 8 -week -old syngeneic C57Bl /6 were obtained ( Charles River, Wilmington, MA ). Following intraperitoneal anesthesia using ketamine (30 mg /kg ) and xylazine ( 30 mg /kg ), the right corpus striatum was stereotactically inoculated with 10 4 GL26 glioma cells in 2.5 L of 1.2% methylcellulose /MEM. On day 4 postimplantation, animals received treatments of 5Â10 8 plaque -forming units (pfu ) of recombinant adenoviral vectors (AdmIFNg, AdTNFa, a combination of AdmIFNg and AdTNFa, or AdLacZ ) in 2.5 L of serum -free medium, injected directly into the established tumor using the previously created burr hole and the same stereotactic coordinates. Saline-treated animals were injected intracranially with an equal volume of normal saline. To investigate whether intracarotid infusion of AdTNFa would affect glioma MHC expression and T-cell content, we implanted Wistar rats (Harlan Sprague -Dawley, Indianapolis, IN ) under intraperitoneal ketamine ( 50 mg /kg ) and xylazine ( 4 mg /kg ) anesthesia with 10 5 RG -2 cells in the right corpus striatum using a stereotactic frame. Four days following tumor implantation, rats were again placed under ketamine and xylazine anesthesia and their right internal carotid artery was cannulated as previously described. 29 Bradykinin ( 10 g /kg ) was infused through this cannula over 10 minutes followed by a 5-minute infusion of 10 10 pfu of either AdTNFa or AdLacZ in 1 mL of serum -free media. All animals were handled and cared for in strict accordance with the Animal Care and Use Committee guidelines in force at Cedars -Sinai Medical Center.
Determination of tumor size
One week following viral inoculations, mice were euthanized using CO 2 asphyxiation, and their brains harvested and frozen immediately with dry ice. Brains were sectioned using a cryostat into 10 -m -thick slices, which were mounted on slides and then stained with hematoxylin and eosin ( H&E ) as per standard protocols. Tumor size was determined as previously described 30 by making serial H&E -stained coronal sections spaced 300 m apart from three to four brains belonging to each treatment group. The section bearing tumor with the maximum visible diameter was identified and scanned into a computer. The software package ''NIH Image'' was then used to calculate tumor area on the scanned section. The visible tumor boundaries were demarcated on screen and the software package calculated the number of pixels in the delineated area. The pixel count was then normalized to the original dimensions of the sections and the tumor area in square millimeters was derived.
Immunohistochemistry
Brain tissue for histological and histochemical examination was obtained from both mice and rats euthanized using CO 2 asphyxiation, 1 week following viral or saline inoculations. Harvested brains were frozen immediately in dry ice and sectioned using a cryostat into 10-m -thick slices, which were mounted on slides and allowed to air dry overnight. 
Quantification of CD4
+ and CD8 + tumor -infiltrating lymphocytes As previously described, 13, 31 two separate stained histological sections from two different animals from each of the intracranially treated glioma -bearing murine groups were used for quantification of CD4 + and CD8 + tumorinfiltrating cells. For each section, positive cells from three random fields, measuring 0.196 mm 2 each, were counted under a light microscope by two investigators blinded to animal history. Values from each investigator for each field were averaged.
Results
In vitro infection of GL26 cells using AdmIFNg and AdTNFa
To determine whether infection of glioma cells with AdmIFNg and AdTNFa produced biologically relevant secretion of each respective cytokine, murine GL26 cells were infected with each virus at different MOIs. Using an MOI of 100 pfu/cell for AdmIFNg, secretion of 1.26 ng/ mL /10 5 GL26 cells per 24 hours was confirmed with ELISA. GL26 cells, when infected with AdTNFa at an MOI of 10, were found to secrete 232 pg /mL /10 5 cells per 24 hours. Strong cytokine secretion was also detectable when GL26 cells were coinfected with both viruses at similar MOIs as above (747 pg /mL /10 5 GL26 cells per 24 hours of IFNg and 104 pg/ mL / 10 5 GL26 cells per 24 hours of TNFa ).
Glioma -bearing mice treated with AdmIFNg and AdTNFa demonstrate prolonged survival
C57Bl/ 6 mice were divided into five treatment groups. Each group received intracranial implantations of GL26 tumors followed 4 days later by intratumoral inoculations of AdmIFNg (n =18), AdTNFa (n = 18), a combination of AdmIFNg and AdTNFa (n =17), AdLacZ (n =15), or normal saline (n = 9). Animals treated with AdmIFNg, AdTNFa, or a combination of the two survived longer than AdLacZ -or saline -treated controls (Fig 1; saline group not shown ). The survival advantage conferred by any of the three treatment groups was statistically significant when compared to either of the control groups in combination or alone (log rank test: P=.0135, AdmIFNg versus AdLacZ; P= .007, AdTNFa versus AdLacZ; P= .004, AdmIFNg + AdTNFa versus AdLacZ ). There were, however, no statistically detectable differences in survival among the three cytokine -treated groups, or between the two control groups ( log rank test: P=.170, AdLacZ versus saline ).
Effect of cytokine gene therapy on in vivo tumor growth
We sought to determine whether the prolongation of survival seen in the three cytokine -treated groups was due to inhibition of tumor growth. Two weeks following intracranial inoculation of virus, mice were sacrificed and tumor volumes determined. Differences in tumor size between the treatment groups are illustrated in Figure 2 . The average maximal tumor area for the AdLacZ -treated group was 2.7± 0.34 mm 2 (mean ± SD ) (n = 3), whereas those for the treatment groups were 0.90± 0.30 mm 2 for AdmIFNg ( n =3 ), 1.12 ± 0.56 for AdTNFa (n = 4), and 1.00± 0.36 for AdmIFNg + AdTNFa ( n= 4). The maximum tumor surface areas detected in the cytokine -treated groups were significantly less than in the control tumors (Student's t test: Figure 1 Kaplan -Meier curve illustrates the effect of IFNg and / or TNFa gene delivery on survival in intracranial GL26 glioma -bearing C57Bl / 6 mice. Intracranial therapy with AdmIFNg, AdTNFa, or a combination of AdmIFNg and AdTNFa significantly prolonged survival when compared to AdLacZ -treated controls ( log rank test: P = .007, AdTNFa versus AdLacZ; P = .0135, AdmIFNg versus AdLacZ; P = .004, AdmIFNg + AdTNFa versus AdLacZ ). There was no statistically detectable difference in survival among any of the three cytokine -treated groups. Figure 2 Effect of IFNg and / or TNFa gene therapy on intracranial tumor volume. C57Bl / 6 mice were stereotactically implanted with GL26 tumors in the right corpus striatum. Treatment consisted of subsequent intratumoral inoculations of AdmIFNg, AdTNFa, a combination of AdmIFNg and AdTNFa, or AdLacZ. Two weeks following implantation, tumor size was determined. Tumors treated with cytokine gene -bearing adenovirus were significantly smaller than AdLacZ -treated controls ( Student's t test: P = .002, AdmIFNg versus AdLacZ; P = .005, AdTNFa versus AdLacZ; P = .001, AdmIFNg + AdTNFa versus AdLacZ ). There was no statistically detectable difference in tumor size among any of the three cytokine -treated groups. Error bars represent SD. 
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T -cell infiltration
To visualize tumor T-cell infiltration, immunohistochemistry was performed on frozen brain sections from all treated groups 2 weeks following intracranial inoculations. T-cell content for both CD4 + and CD8 + cells was substantially increased in sections derived from tumors treated with AdmIFNg, AdTNFa, and both AdmIFNg and AdTNFa ( Fig 3) . All of these sections demonstrated visibly smaller tumors with significantly higher immune cell infiltration than controls. CD4 + and CD8 + T-cell infiltration was significantly higher in AdmIFNg, AdTNFa, and cotreated tumors compared to AdLacZ -treated controls (P < .05, Positively stained cells from two separate histological sections, originating from two separate animals from each treatment group, were quantified ( E ). The increased CD4 + and CD8 + T -cell infiltration observed in cytokine -treated tumors was statistically significant ( Student's t test: P < .01, AdmIFNg, AdTNFa, or AdmIFNg + AdTNFa versus AdLacZ ). All photomicrographs represent Â400 magnification. Error bars in ( E ) represent SD.
Student's t test ). There were no significant differences in TIL infiltration within the three cytokine -treated groups. To determine the viability of intravascular gene delivery and its potential to enhance intratumoral T-cell infiltration, we delivered AdTNFa intraarterially to glioma -bearing rats. This resulted in increased perivascular infiltrates of CD4 (Fig 4, A and B , respectively ). C57Bl /6 mice bearing intracranial GL26 gliomas received intratumoral inoculations of AdmIFNg, AdTNFa, a combination of AdmIFNg and AdTNFa, or AdLacZ. Five days following inoculation of virus, tumors were harvested and immunohistochemistry was performed on frozen sections of the tumor to detect MHC -I and -II ( Fig 4 ) . AdmIFNg induced robust in vivo up-regulation of MHC -I expression on GL26 cells, whereas AdTNFa treatment resulted in increased MHC -II expression. Up -regulation of MHC -I with AdTNFa treatment and of MHC -II with AdmIFNg treatment was present, but less striking (data not shown ).
To determine whether AdTNFa-induced MHC -II upregulation could be detected in an alternate tumor model using a different delivery methodology, we performed intracarotid infusion of AdTNFa in Wistar rats bearing RG2 gliomas. Five days following this infusion, tumors were harvested and frozen sections were analyzed with immunohistochemistry for MHC -II expression. Significant up -regulation of MHC -II was evident on tumor vascular endothelium and perivascular tissue (Fig 5 ) .
AdmIFNg and AdTNFa treatment induces apoptosis in GL26 glioma cells and HUVEC cells
We wished to investigate the potential for IFNg -and TNFa -induced apoptosis in glioma cells and endothelial cells. GL26 cells and HUVEC cells were infected in vitro with AdmIFNg, AdTNFa, a combination of AdmIFNg and AdTNFa, and AdLacZ. Forty -eight hours following infection, apoptotic activity was assessed using a terminal deoxynucleotide transferase-mediated nick end labeling ( TUNEL ) assay (Fig 6 ) . Significant apoptosis was detectable in GL26 cells infected with AdTNFa ( Fig 6C ) , as well as a combination of AdmIFNg and AdTNFa (not shown). In addition, HUVEC cultures cotreated with AdmIFNg and AdTNFa also demonstrated the presence of numerous apoptotic cells ( Fig 6D ) . In addition, in vivo GL26 tumors treated with AdTNFa ( Fig 6E ) and a combination of AdTNFa and AdmIFNg ( not shown ) demonstrated visibly necrotic areas in the tumor center not seen in tumors treated with AdmIFNg alone or AdLacZ. We were, however, not able to detect any significant decrease in tumor vascular density ( normalized for tumor size ) in any of the treated mice compared to controls using immunohistochemistry for Von Willebrand Factor (data not shown ), indicating that, in our model, in vivo inhibition of angiogenesis did not represent an important tumoricidal and/ or tumoristatic mechanism.
Tumor -associated endothelium expresses FasL and this expression is down -regulated by AdTNFa treatment
With the aim of determining whether tumor-associated endothelium expressed FasL and whether such expression could be modulated with cytokine gene therapy, we performed immunohistochemistry for FasL and Von Willebrand Factor ( an endothelial cell marker ) on frozen tumor sections taken from C57Bl/ 6 glioma -bearing brains, which had been inoculated with AdmIFNg, AdTNFa, a combination of AdmIFNg and AdTNFa, or AdLacZ. Cancer Gene Therapy ( Fig 7B ) .
Discussion
Patients with high -grade gliomas exhibit decreased peripheral T-cell responsiveness as well as overall decreased immune function. 7 In addition, local intratumoral immune cells in gliomas are generally dysfunctional, 32 and tumorinfiltrating T cells have been found to polarize chiefly towards a Th -2 state of activation, which supports humoral immunity at the expense of a Th -1 response that is necessary 
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for effective cell -mediated immune killing of neoplasms. 33 Gliomas, therefore, exert immunosuppressive effects at both the local and systemic levels. This may be due, in part, to the active expression of immune -suppressing cytokines, 34 which inhibit T-cell and antigen -presenting cell function, 35 as well due to the failure of glioma cells to express adequate levels of MHC on their surface, thereby depriving TIL with signals necessary for recognizing tumor antigens. 23 In addition, glioma cells may induce the local expression of certain proteins, such as FasL, which may directly engage and induce apoptosis in T cells, thereby inhibiting their movement into and through neoplastic tissue. 36 The use of cytokine therapy to address glioma immune privilege has been extensively investigated. The systemic use of recombinant cytokines in humans is, with limited exception, precluded by concerns of toxicity and inadequate half -life. 3, 4 Additionally, systemic therapies fail to adequately address local factors in the tumor microenvironment that contribute to the regional immunosuppression associated with malignant brain tumors. An important therapeutic strategy that aims to address these concerns is in situ cytokine gene transfer, which circumvents the problems associated with peripheral toxicity and subtherapeutic protein half -life of systemically or locally administered recombinant cytokine. Local gene therapy of glioma with interleukin -4 37 and interleukin -12 13 has resulted in tumor regression with improved survival. IFNg and TNFa have also been delivered locally to brain tumors with encouraging results. (1.5Â10 3 ), rapidly followed 2 days later by in situ inoculation with adenovirus -encoding IFNg. This model reports no intratumoral immune cell activity whatsoever and attributes its demonstrated survival benefit to antiangiogenic properties of IFNg as demonstrated by decreased histological evidence of tumor vascularity. The use of lung carcinoma, rather than glioma, significantly decreases the relevance of this study to primary brain tumor therapy, and the results described cannot, therefore, be interpreted as being representative of IFNg gene therapy for glioma.
TNFa gene transfer to glioma has also resulted in vascular necrosis and tumor cell death, particularly when combined with radiotherapy. Baher et al 38 and Staba et al 39 both utilized TNFa gene therapy in extracranial glioma xenografts and described its use in augmenting radiation -induced neoplastic cell death. Niranjan et al 26 report effective use of a herpes simplex virus (HSV ) to deliver the genes for TNFa and thymidine kinase ( TK ). This HSV vector, when used in combination with radiotherapy, was able to significantly prolong survival in athymic nude mice with human U87 glioblastomas. However, Niranjan et al, 26 as was the case with Baher et al, 38 were unable to describe any significant improvement in tumor killing or survival with the use of TNFa gene transfer alone without adjuvant radiotherapy. Staba et al 39 demonstrated decreased subcutaneous tumor volumes with the use of TNFa gene transfer alone, but did not test their methodology in an intracranial glioma model, nor did they assess the impact of their therapy on survival. These reports all assessed the tumoricidal effects of TNFa gene transfer in immune-incompetent animal models. This precluded them from investigating the powerful immunomodulatory effects of TNFa, and may also explain their failure to detect survival advantages with TNFa gene transfer alone.
We have, for the first time, documented a significant role for both adenoviral -mediated IFNg and TNFa gene transfer in glioma immunotherapy. We demonstrate an increase in tumor MHC expression and enhanced intratumoral CD4 + and CD8 + T-cell infiltration. In addition, AdmIFNg and AdTNFa therapy, alone or in combination, prolonged survival in treated animals compared to controls, a finding not previously reported for established intracranial glioma. It is conceivable that when combined with adjuvant treatment modalities such as radiotherapy or dendritic cell -based vaccination strategies, the therapeutic effect we demonstrate ( exemplified by decreased tumor volume and prolonged survival ) could be magnified.
Despite our confirmation that AdmIFNg and AdTNFa contribute to endothelial cell apoptosis in vitro, we were, in contrast to earlier studies, unable to detect any significant decrease in endothelial cell density in vivo with IFNg and /or TNFa gene therapy. It is possible that subtle differences in biochemical pathways governing neovascular angiogenesis and/or vascular homeostasis between our tumor cell line and host animal strain and those utilized earlier may explain why our model was refractory to the previously described antiangiogenic properties of these two cytokines.
Tumors treated with a combination of both vectors demonstrated significant increases in surface expression of both MHC -I and -II. In contrast, gliomas from mice inoculated with AdmIFNg or AdTNFa alone significantly overexpressed either MHC -I or -II, respectively. Increases in overall MHC -II expression with AdmIFNg therapy and MHC -I expression with AdTNFa treatment were limited and less uniform. Despite additive MHC -I and -II expression in IFNg -and TNFa-cotreated tumors, there were no significant variances in TIL content, tumor size, or survival. Therefore, it appears that the inhibition of tumor growth, enhanced T-cell infiltration, and prolongation of survival demonstrated in our model were also dependent on factors other than MHC modulation.
Endothelial FasL expression may represent an additional barrier to T-cell migration into brain tumors. We wished to investigate whether we could detect and possibly modulate FasL expression in the tumor microenvironment. FasL, a type II cell membrane protein, has been implicated as an agent facilitating immune escape by a variety of cancers including ovarian carcinoma, 40 melanoma, 41 colon carcinoma, 42 breast carcinoma, 43 esophageal carcinoma, 44 and glioma. 36 It is postulated that FasL mediates immune evasion through engagement of Fas receptors on the surface of T cells, thereby inducing them to undergo apoptosis. Recently, evidence that implicates endothelial expression of FasL as inhibitory to immune cell trafficking across vascular epithelium has also surfaced. 27 Endothelial FasL expression can be down -regulated with TNFa therapy, resulting in increased leukocyte extravasation. 45 We have previously demonstrated significant expression of FasL on brain tumor endothelium in tumor tissue derived from high -grade human gliomas (submitted for publication ). We wished to determine the extent and distribution of FasL expression in our rodent glioma models, and whether any such expression could be modulated with cytokine gene therapy. We were not able to detect FasL expression on the surface of either GL26 or RG -2 cells. However, endothelial cells within GL26 tumors, but not within normal brain, were found to be positive for FasL. This robust expression was not seen in tumors treated with AdTNFa alone and was greatly diminished in tumors inoculated with a combination of AdTNFa and AdmIFNg. We postulate that endothelial expression of FasL may contribute to immune evasion in brain tumors by restricting T-cell trafficking across the tumor -capillary barrier. Part of TNFa's ability to support antitumor immune responses may stem from a downregulation of endothelial FasL, thereby removing this impediment to T-cell translocation. However, as TNFa exerts its immunostimulatory effects through a plethora of pathways, it would be necessary to control for its pluripotency before any conclusive evidence regarding this potential phenomenon can be generated.
Our results indicate that local intraglioma IFNg and TNFa gene transfer results in enhanced lymphocytic infiltration of tumors accompanied by decreased tumor size and prolonged survival. We demonstrate that these effects are associated with enhanced MHC expression on tumor cells as well as increased necrotic activity in TNFa-treated tumors. Therefore, in addition to effecting a direct tumoricidal effect, intratumoral secretion of IFNg and TNFa may serve to overcome local glioma -induced barriers to immune access. These findings illustrate the effectiveness of IFNg and TNFa gene therapy as a treatment strategy for glioma, and add further weight to the necessity of developing and pursuing therapeutic strategies that focus on enhancing local intratumoral immune activity.
